Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1998-07-31
2001-01-23
Rose, Shep K. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S369000, C514S562000, C514S547000, C514S956000
Reexamination Certificate
active
06177434
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a method and composition for preventing and/or reversing sensorineural hearing loss (SNHL) or toxin-induced hearing loss. More specifically, this invention relates to the use of agents which augment inner ear antioxidant defenses such as adenosine agonists or up-regulating agents and/or agents which increase inner ear glutathione levels to prevent and/or reverse hearing loss induced by noise or toxin. In addition, this invention covers agents that curtail activated programmed cell death pathways and induce/enhance cell repair mechanisms in the inner ear.
2. Description of the Prior Art
SNHL is a very common problem for service members and civilian government employees. Approximately 450 million dollars is spent annually to compensate service members for hearing loss (1). Despite hearing conservation programs, 20-30% of service members develop compensable hearing loss after 10 years in the service (2). The sense of hearing is critical for combat and operational readiness of soldiers and sailors. Both temporary and permanent hearing threshold impairments decrease the ability to communicate and to detect enemy movements (3). Successful implementation of medical treatment to prevent or reverse SNHL as an augmentation to established hearing conservation programs has the potential to save millions of dollars annually and to significantly improve operational readiness.
It is established by the Center for Disease Control that approximately 30 million people in the U.S. suffer from SNHL (4). The potential for commercialization is very extensive and would include workers in factories, construction operations, communications, and the airline industry to name a few. Many people working in an environment with damaging noise or toxins would potentially benefit from this treatment. In addition, individuals receiving toxic medications for other forms of therapy (i.e. cancer chemotherapy) can suffer SNHL. An idiopathic form of SNHL also exists.
Currently there are no published effective topical medications to prevent or reverse SNHL. There are no published reports of topical, oral, or systemic medications to treat noise-induced hearing loss (NIHL). This invention differs from mechanical noise attenuators or hearing protection devices in that it does not need to be worn and does not decrease hearing acuity as hearing protectors do. Also, this treatment has the potential to reverse SNHL after it is occurred.
Additionally, cisplatin and aminoglycoside antibiotics such as gentamicin represent useful commonly prescribed therapeutic agents which are toxic to the ear and cause sensorineural hearing loss (
6
,
7
,
15
). Gentamicin is used as an agent delivered indirectly to the inner ear via the middle crossing the round window membrane to destroy balance function in an inner ear affected by Meniere's disease (
28
). One of the limitations of this therapy is that the auditory portion of the inner ear is also often damaged leading to sensorineural hearing loss (
29
). Thus there is a need to selectively protect the auditory hair cells while eliminating inner ear balance function with the gentamicin.
SUMMARY OF THE INVENTION
Accordingly, an object of this invention is to prevent sensorineural hearing loss and sensorineural hearing loss caused by noise.
A further object of this invention is to reverse sensorineural hearing loss and sensorineural hearing loss induced by noise.
Yet another object of the invention is to prevent and or reverse hearing loss by the topical application of a compound or combination of compounds which increase inner ear glutathione (GSH) levels and/or augment other inner ear antioxidant defenses, and agents that curtail activated programmed cell death pathways and/or induce/enhance cell repair mechanisms in the inner ear.
Another object of the invention is to protect auditory hair cells from toxic injury by cisplatin or gentamicin.
These and additional objects of the invention are accomplished by preventing and/or reversing inner ear damage due to noise or toxins by upregulating antioxidant enzyme activity by applying agents such as R-N6-Phenylisopropyl adenosine (R-PIA) to the round window membrane of the inner ear or systemically, and/or by also applying agents such as 1-2-oxothiazolidine-4-carboxylic acid (Procysteine) to the round window membrane or by giving it systemically. Selective auditory hair cell protection in the face of gentamicin exposure by concomitant delivery of an NMDA antagonist or glial derived neurotrophic factor (GDNF) with the gentamicin. These and additional agents are also accomplished by curtailing activated programmed cell death pathways and/or inducing/enhancing cell repair mechanisms in the inner ear.
The agent (s) may be applied before, during or after the noise trauma or toxin exposure. Currently there is no published effective topical medication to prevent or reverse SNHL, no published effective medication to prevent or reverse NIHL, and no published medical therapy to selectively protect auditory hair cells from gentamicin toxicity. This invention differs from mechanical noise attenuators or hearing protection devices in that it does not need to be worn and does not decrease hearing acuity as hearing protectors do. Also, this treatment has the potential to reverse SNHL or toxic hearing loss after it is occurred.
REFERENCES:
patent: 5929041 (1999-07-01), Magal et al.
Hu et al., R-phenylisopropyladenosine attenuates noise-induced hearing loss in the chinchilla; Hearing Research; pp. 198-206, Nov. 1997.
Henderson Donald
Hoffer Michael E.
Kopke Richard D.
Jagoe Donna
McDonnell Thomas E.
Rose Shep K.
Spevack A. David
The United States of America as represented by the Secretary of
LandOfFree
Prevention or reversal of sensorineural hearing loss (SNHL)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention or reversal of sensorineural hearing loss (SNHL)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention or reversal of sensorineural hearing loss (SNHL)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2483741